[vc_row][vc_column width=”1/4″ enable_sticky=”true” sticky_offset=”0″ offset=”vc_hidden-xs”][vc_wp_custommenu nav_menu=”18″][/vc_column][vc_column width=”3/4″][vc_column_text]Direct links to select peer-reviewed journal articles regarding ceragenins can be found below:
[/vc_column_text][vc_separator][vc_column_text]
Ceragenins are Highly Effective Against Antimicrobial-Resistant Pathogens:
Bactericidal Activity of Ceragenin in Combination with Ceftazidime, Levofloxacin, Co-Trimoxazole, and Colistin against the Opportunistic Pathogen Stenotrophomonas maltophilia. Paprocka P, Mańkowska A, Skłodowski K, Król G, Wollny T, Lesiak A, Głuszek K, Savage PB, Durnaś B, Bucki R (2022).
Ceragenins and Antimicrobial Peptides Kill Bacteria through Distinct Mechanisms. Mitchell G, Silvis MR, Talkington KC, Budzik JM, Dodd CE, Paluba JM, Oki EA, Trotta KL, Licht DJ, Jimenez-Morales D, Chou S, Savage PB, Gross CA, Marletta MA, Cox JS (2022).
Antibacterial and antibiofilm activities of ceragenins against Achromobacter species isolated from cystic fibrosis patients. Damar-Çelik D, Mataracı-Kara E, Savage PB, Özbek-Çelik B (2020).
NDM-1 Carbapenemase-Producing Enterobacteriaceae are Highly Susceptible to Ceragenins CSA-13, CSA-44, and CSA-131. Chmielewska SJ, Skłodowski K, Piktel E, Suprewicz Ł, Fiedoruk K, Daniluk T, Wolak P, Savage PB, Bucki R (2020).
New β-Lactam Antibiotics and Ceragenins – A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of Pseudomonas aeruginosa. Paprocka P, Durnaś B, Mańkowska A, Skłodowski K, Król G, Zakrzewska M, Czarnowski M, Kot P, Fortunka K, Góźdź S, Savage PB, Bucki R (2021).
Candidacidal Activity of Selected Ceragenins and Human Cathelicidin LL-37 in Experimental Settings Mimicking Infection Sites. Durnaś B, Wnorowska U, Pogoda K, Deptuła P, Wątek M, Piktel E, Głuszek S, Gu X, Savage PB, Niemirowicz K, Bucki R (2016).
Proteomic Analysis of Resistance of Gram-Negative Bacteria to Chlorhexidine and Impacts on Susceptibility to Colistin, Antimicrobial Peptides, and Ceragenins. Hashemi MM, Holden BS, Coburn J, Taylor MF, Weber S, Hilton B, Zaugg AL, McEwan C, Carson R, Andersen JL, Price JC, Deng S, Savage PB (2019).
Susceptibility of Colistin-Resistant, Gram-Negative Bacteria to Antimicrobial Peptides and Ceragenins. Hashemi MM, Rovig J, Weber S, Hilton B, Forouzan MM, Savage PB (2017).
Preclinical testing of a broad-spectrum antimicrobial endotracheal tube coated with an innate immune synthetic mimic. Hashemi MM, Rovig J, Bateman J, Holden BS, Modelzelewski T, Gueorguieva I, von Dyck M, Bracken R, Genberg C, Deng S, Savage PB (2018).
Bactericidal activities of cathelicidin LL-37 and select cationic lipids against the hypervirulent Pseudomonas aeruginosa strain LESB58. Wnorowska U, Niemirowicz K, Myint M, Diamond SL, Wróblewska M, Savage PB, Janmey PA, Bucki R (2015).
Comparative In Vitro Activities of First and Second-Generation Ceragenins Alone and in Combination with Antibiotics Against Multidrug-Resistant Klebsiella pneumoniae Strains. Ozbek-Celik B, Damar-Celik D, Mataraci-Kara E, Bozkurt-Guzel C, Savage PB (2019).
In Vitro Activities of the Cationic Steroid Antibiotics CSA-13, CSA-131, CSA-138, CSA-142, and CSA-192 Against Carbapenem-resistant Pseudomonas aeruginosa. Bozkurt Güzel Ç, Avci NM, Savage P (2020).
CSA-131, a ceragenin active against colistin-resistant Acinetobacter baumannii and Pseudomonas aeruginosa clinical isolates. Xavier Vila-Farrés, Anna Elena Callarisa, Xiaobo Gu, Paul B. Savage, Ernest Giralt, Jordi Vila. (2015).
[/vc_column_text][vc_separator][vc_column_text]Direct links to select articles relevant to the ceragenin technology and N8 Medical’s products under development can be found below:
[/vc_column_text][vc_column_text]Policy Documents
[/vc_column_text][/vc_column][/vc_row]